February 14, 2017
Chi-Med kicks off human testing of its anti-tumor inhibitor
Hutchison China MediTech Limited (Chi-Med) has kicked off today in Australia the first-in-human (FIH) Phase I clinical testing of inhibitor HMPL-453, for fibroblast growth factor receptor signaling pathway, which forces tumor growth.